Lung Cancer News and Research

Latest Lung Cancer News and Research

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Asbestos awareness important to prevent related cancer: Experts

Experts from Perth speculate Western Australia is yet to see the peak of asbestos-induced cancer, with renovators still failing to take proper precautions. According to director of the National Centre for Asbestos Related Diseases, Bruce Robinson, the next and third wave of mesothelioma patients would come out of those putting themselves and others at risk while taking on DIY home renovation projects.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Cascade Technologies, Corp. announced today that, in response to significant recent attention to the Food and Drug Administration (FDA) panel evaluation of Mela Sciences' MelaFind device, the company has received a number of inquiries about its similar instrument.

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.

20 Nov 2010

Consuming a variety of fruit reduces lung cancer risk by 23%

Eating five portions of fruit and vegetables per day is one of the means that experts most frequently recommend for preventing cancer. Now, the European EPIC study carried out by researchers from 10 countries has shown that, in the case of lung cancer, the important thing is not just the quantity but also the variety of fruit consumed, which can reduce the risk by up to 23%.

20 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

ProvenCare to focus on potential problems in lung cancer patients

Northwestern Memorial Hospital is one of six national participants in a pilot study that will test whether operable lung cancer patients and their families have a smoother care experience and better outcomes by hardwiring data systems to reduce medical error and to reliably adhere to best practice standards.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

19 Nov 2010

Uniting announces recipient of 'Caine Halter Hope Now Award for Lung Cancer Research'

Uniting Against Lung Cancer (Uniting) announces the "Caine Halter Hope Now Award for Lung Cancer Research."

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Asbestos awareness important to prevent related cancer: Experts

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

IsoRay to sell $2.25 million in common stock

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Consuming a variety of fruit reduces lung cancer risk by 23%

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

ProvenCare to focus on potential problems in lung cancer patients

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Uniting announces recipient of 'Caine Halter Hope Now Award for Lung Cancer Research'

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in